Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin versus sitagliptin for left ventricular function in type 2 diabetes
2016-002225-10Phase 3Completed
- Sponsor
- Azienda Ospedaliero-Universitaria Pisana
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing Empagliflozin arm with Sitagliptin arm (2 arms). Primary endpoint: Change in global longitudinal strain. Started Jun 2021; status: completed.
02
Drugs
empagliflozinsitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2016-002225-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002225-10.